the vision to heal

The potential to simulate natural healing


Noveome is advancing its ST266 platform biologic, a first-of-its-kind, multi-targeted secretome containing hundreds of biologically active proteins and other factors crucial to neuroprotection, the modulation of inflammation, cell recovery and healing. We believe this novel platform biologic holds significant clinical potential across a range of important underserved conditions in ophthalmology, neurology, dermatology—and beyond.

exciting science

Learn more about ST266 and its unique and powerful healing potential.

advancing pipeline

Explore our portfolio covering a range of important ophthalmic indications.

rewarding careers

Join a passionate, diverse team dedicated to making a positive difference in patients’ lives.

making news

May 12, 2020

Singota Solutions, a pharmaceutical contract development and manufacturing organization, will manufacture Noveome’s lead candidate for Phase I / II clinical…

May 7, 2020

Funding Enables Existing Clinical Trials to Proceed as Company Joins Global Response with COVID-19 Program   PITTSBURGH – May 7,…

March 30, 2020

ST266 may significantly mitigate the frequently fatal cytokine storm observed in COVID-19 patients Plans to initiate human clinical trial by…